Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lerisetron vs Granisetron for Radiotherapy-Induced Nausea and Vomiting in Stage I Seminoma
NCT00004219Phase 3Unknown
- Sponsor
- Simbec-Orion
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of lerisetron in Nausea and Vomiting (3 arms), sponsored by Simbec-Orion. Primary endpoint: Efficacy in the prevention of radiotherapy induced nausea and vomiting at 10 days. Status: unknown.
02
Drugs
lerisetron
03
Conditions
Nausea and Vomiting
Beyond the preview
Go deeper on NCT00004219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004219.